# QuantumScape Corp: financial statements, quarterly

QS · Nasdaq · CIK 1811414 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qs.md) · [Financials](/companies/qs/financials.md) · [Filings](/companies/qs/filings.md) · [Insiders](/companies/qs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [96.4 d](/filings/0001193125-26-071556.md) | [83.8](/filings/0000950170-25-058706.md) | [97.7](/filings/0000950170-25-098777.md) | [97.0](/filings/0001193125-25-249971.md) | [104 d](/filings/0001193125-26-071556.md) | [95.6](/filings/0001193125-26-177161.md) | [101](/filings/0001193125-26-316073.md) | [92.1](/filings/0001193125-26-430428.md) | [86.8 d](/filings/0001193125-26-071556.md) | [84.6](/filings/0001193125-26-177161.md) | [82.5](/filings/0001193125-26-316073.md) | [73.9](/filings/0001193125-26-430428.md) |
| Operating income | $m | [(125) d](/filings/0001193125-26-071556.md) | [(132)](/filings/0000950170-25-058706.md) | [(134)](/filings/0000950170-25-098777.md) | [(130)](/filings/0001193125-25-249971.md) | [(129) d](/filings/0001193125-26-071556.md) | [(124)](/filings/0001193125-26-177161.md) | [(124)](/filings/0001193125-26-316073.md) | [(115)](/filings/0001193125-26-430428.md) | [(110) d](/filings/0001193125-26-071556.md) | [(109)](/filings/0001193125-26-177161.md) | [(106)](/filings/0001193125-26-316073.md) | [(92.4)](/filings/0001193125-26-430428.md) |
| Interest expense | $m | [0.6 d](/filings/0000950170-24-021100.md) | [0.6](/filings/0000950170-24-049080.md) | [0.6](/filings/0000950170-24-086884.md) | [0.6](/filings/0001193125-25-249971.md) | [0.5 d](/filings/0001193125-26-071556.md) | [0.5](/filings/0001193125-26-177161.md) | [0.5](/filings/0001193125-26-316073.md) | [0.5](/filings/0001193125-26-430428.md) | [0.5 d](/filings/0001193125-26-071556.md) | [0.5](/filings/0001193125-26-177161.md) | [0.5](/filings/0001193125-26-316073.md) | [0.5](/filings/0001193125-26-430428.md) |
| Income tax | $m | [0.0 d](/filings/0001193125-26-071556.md) | [0.0](/filings/0000950170-25-058706.md) | [0.0](/filings/0000950170-25-098777.md) | [0.0](/filings/0001193125-25-249971.md) | [(0.3) d](/filings/0001193125-26-071556.md) | [0.2](/filings/0001193125-26-177161.md) | [(0.2)](/filings/0001193125-26-316073.md) | [1.2](/filings/0001193125-26-430428.md) | [0.4 d](/filings/0001193125-26-071556.md) | [0.0](/filings/0001193125-26-177161.md) | [0.2](/filings/0001193125-26-316073.md) | [0.1](/filings/0001193125-26-430428.md) |
| Net income | $m | [(113) d](/filings/0001193125-26-071556.md) | [(121)](/filings/0000950170-25-058706.md) | [(123)](/filings/0000950170-25-098777.md) | [(120)](/filings/0001193125-25-249971.md) | [(115) d](/filings/0001193125-26-071556.md) | [(114)](/filings/0001193125-26-177161.md) | [(115)](/filings/0001193125-26-316073.md) | [(106)](/filings/0001193125-26-430428.md) | [(100) d](/filings/0001193125-26-071556.md) | [(101)](/filings/0001193125-26-177161.md) | [(98.2)](/filings/0001193125-26-316073.md) | [(84.5)](/filings/0001193125-26-430428.md) |
| Diluted EPS | $ per share | not reported | [(0.24)](/filings/0000950170-25-058706.md) | [(0.25)](/filings/0000950170-25-098777.md) | [(0.23)](/filings/0001193125-25-249971.md) | not reported | [(0.21)](/filings/0001193125-26-177161.md) | [(0.20)](/filings/0001193125-26-316073.md) | [(0.18)](/filings/0001193125-26-430428.md) | not reported | [(0.16)](/filings/0001193125-26-177161.md) | [(0.16)](/filings/0001193125-26-316073.md) | [(0.14)](/filings/0001193125-26-430428.md) |
| Basic EPS | $ per share | not reported | [(0.24)](/filings/0000950170-25-058706.md) | [(0.25)](/filings/0000950170-25-098777.md) | [(0.23)](/filings/0001193125-25-249971.md) | not reported | [(0.21)](/filings/0001193125-26-177161.md) | [(0.20)](/filings/0001193125-26-316073.md) | [(0.18)](/filings/0001193125-26-430428.md) | not reported | [(0.16)](/filings/0001193125-26-177161.md) | [(0.16)](/filings/0001193125-26-316073.md) | [(0.14)](/filings/0001193125-26-430428.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [143](/filings/0001193125-26-071556.md) | [192](/filings/0000950170-25-058706.md) | [196](/filings/0000950170-25-098777.md) | [175](/filings/0001193125-25-249971.md) | [141](/filings/0001193125-26-071556.md) | [154](/filings/0001193125-26-177161.md) | [172](/filings/0001193125-26-316073.md) | [226](/filings/0001193125-26-430428.md) | [231](/filings/0001193125-26-430428.md) | [145](/filings/0001193125-26-177161.md) | [133](/filings/0001193125-26-316073.md) | [75.6](/filings/0001193125-26-430428.md) |
| Current assets | $m | [1,084](/filings/0000950170-25-027308.md) | [1,045](/filings/0000950170-24-049080.md) | [973](/filings/0000950170-24-086884.md) | [854](/filings/0000950170-24-117409.md) | [922](/filings/0001193125-26-071556.md) | [871](/filings/0000950170-25-058706.md) | [806](/filings/0000950170-25-098777.md) | [1,016](/filings/0001193125-25-249971.md) | [982](/filings/0001193125-26-430428.md) | [916](/filings/0001193125-26-177161.md) | [869](/filings/0001193125-26-316073.md) | [833](/filings/0001193125-26-430428.md) |
| Total assets | $m | [1,502](/filings/0000950170-25-027308.md) | [1,464](/filings/0000950170-24-049080.md) | [1,397](/filings/0000950170-24-086884.md) | [1,272](/filings/0000950170-24-117409.md) | [1,322](/filings/0001193125-26-071556.md) | [1,259](/filings/0000950170-25-058706.md) | [1,168](/filings/0000950170-25-098777.md) | [1,343](/filings/0001193125-25-249971.md) | [1,308](/filings/0001193125-26-430428.md) | [1,229](/filings/0001193125-26-177161.md) | [1,169](/filings/0001193125-26-316073.md) | [1,119](/filings/0001193125-26-430428.md) |
| Current liabilities | $m | [57.1](/filings/0000950170-25-027308.md) | [101](/filings/0000950170-24-049080.md) | [112](/filings/0000950170-24-086884.md) | [60.7](/filings/0000950170-24-117409.md) | [64.9](/filings/0001193125-26-071556.md) | [52.3](/filings/0000950170-25-058706.md) | [49.2](/filings/0000950170-25-098777.md) | [48.0](/filings/0001193125-25-249971.md) | [61.5](/filings/0001193125-26-430428.md) | [43.8](/filings/0001193125-26-177161.md) | [47.2](/filings/0001193125-26-316073.md) | [51.8](/filings/0001193125-26-430428.md) |
| Total liabilities | $m | [162](/filings/0000950170-25-027308.md) | [204](/filings/0000950170-24-049080.md) | [215](/filings/0000950170-24-086884.md) | [161](/filings/0000950170-24-117409.md) | [165](/filings/0001193125-26-071556.md) | [150](/filings/0000950170-25-058706.md) | [144](/filings/0000950170-25-098777.md) | [127](/filings/0001193125-25-249971.md) | [139](/filings/0001193125-26-430428.md) | [119](/filings/0001193125-26-177161.md) | [121](/filings/0001193125-26-316073.md) | [124](/filings/0001193125-26-430428.md) |
| Shareholders' equity | $m | [1,338](/filings/0001193125-26-071556.md) | [1,258](/filings/0000950170-25-098777.md) | [1,180](/filings/0001193125-25-249971.md) | [1,111](/filings/0001193125-25-249971.md) | [1,158](/filings/0001193125-26-430428.md) | [1,109](/filings/0001193125-26-316073.md) | [1,025](/filings/0001193125-26-430428.md) | [1,216](/filings/0001193125-26-430428.md) | [1,169](/filings/0001193125-26-430428.md) | [1,110](/filings/0001193125-26-316073.md) | [1,048](/filings/0001193125-26-430428.md) | [995](/filings/0001193125-26-430428.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(57.5) d](/filings/0001193125-26-071556.md) | [(57.9)](/filings/0000950170-25-058706.md) | [(65.2) d](/filings/0000950170-25-098777.md) | [(92.8) d](/filings/0001193125-25-249971.md) | [(58.7) d](/filings/0001193125-26-071556.md) | [(60.7)](/filings/0001193125-26-177161.md) | [(61.8) d](/filings/0001193125-26-316073.md) | [(63.7) d](/filings/0001193125-26-430428.md) | [(56.2) d](/filings/0001193125-26-071556.md) | [(59.5)](/filings/0001193125-26-177161.md) | [(56.7) d](/filings/0001193125-26-316073.md) | [(55.1) d](/filings/0001193125-26-430428.md) |
| Capital expenditure | $m | [13.9 d](/filings/0001193125-26-071556.md) | [14.1](/filings/0000950170-25-058706.md) | [18.9 d](/filings/0000950170-25-098777.md) | [18.0 d](/filings/0001193125-25-249971.md) | [11.2 d](/filings/0001193125-26-071556.md) | [5.8](/filings/0001193125-26-177161.md) | [8.6 d](/filings/0001193125-26-316073.md) | [9.6 d](/filings/0001193125-26-430428.md) | [12.3 d](/filings/0001193125-26-071556.md) | [10.0](/filings/0001193125-26-177161.md) | [4.6 d](/filings/0001193125-26-316073.md) | [4.4 d](/filings/0001193125-26-430428.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [440](/filings/0000950170-24-049080.md) | [445](/filings/0000950170-24-086884.md) | [472](/filings/0000950170-24-117409.md) | [496](/filings/0000950170-25-058706.md) | [501](/filings/0000950170-25-098777.md) | [509](/filings/0001193125-25-249971.md) | [548](/filings/0001193125-26-177161.md) | [562](/filings/0001193125-26-316073.md) | [589](/filings/0001193125-26-430428.md) | [611](/filings/0001193125-26-177161.md) | [617](/filings/0001193125-26-316073.md) | [621](/filings/0001193125-26-430428.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 95,449,946 at 2022-02-18, from the cover of the [10-K filed 2022-02-28](/filings/0000950170-22-002330.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.